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Summary 
Lipid droplets (LDs) are ubiquitous fat storage organelles and play key roles in lipid metabolism 
and energy homeostasis; in addition, they contribute to protein storage, folding and degradation. 
Yet, a role for LDs in the nervous system remains largely unexplored. We discuss evidence 
supporting an intimate functional connection between LDs and Motor Neuron Disease (MND) 
pathophysiology, examining how LD functions in systemic energy homeostasis, in neuron-glia 
metabolic coupling and protein folding/clearance may affect or contribute to disease pathology. 
An integrated understanding of LD biology and neurodegeneration may open the way for new 
therapeutic interventions.  
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The Basics 
Motor Neuron Diseases (MNDs) are characterized by the gradual degeneration and death of motor 
neurons (MNs), resulting in progressive paralysis and muscle atrophy. Amyotrophic Lateral 
Sclerosis (ALS) is a fatal disease and the most common MND, with a worldwide annual incidence 
of ~1.9 per 100,000 individuals (Arthur et al., 2016). A plethora of genes with a causative role in 
ALS have been identified (Renton et al., 2014). Among the cellular processes implicated in ALS 
pathophysiology are ER stress and protein clearance, neuron-glia metabolic coupling and energy 
homeostasis (Schmitt et al., 2014; Taylor et al., 2016). However, how alterations in these processes 
contribute to the disease remains poorly understood. Recently, connections have emerged between 
MNDs, including ALS, and lipid droplets (LDs), the cellular organelles for fat storage, possibly 
providing a new perspective for understanding disease-related mechanisms. 
LDs are ubiquitous organelles with a unique structure: a core of neutral lipids 
(triacylglycerols (TAGs) and sterol esters) surrounded by a monolayer of phospholipids and 
proteins. LDs originate from the ER and, when lipids are needed, they are turned over by 
cytoplasmic lipases and autophagy. Mechanisms and regulation of LD biogenesis, growth, and 
turnover are active areas of investigation (Qi et al., 2017; Schulze et al., 2017; Walther et al., 
2017). 
LDs play critical roles in cellular processes also implicated in ALS pathophysiology. 
Foremost is their role in energy homeostasis, as they provide Fatty Acid (FA) fuel for ATP 
production. Emerging evidence also links LDs to neuron-glia metabolic coupling (Liu et al., 2017). 
Furthermore, LDs are involved in the resolution of ER stress and the clearing of protein aggregates 
(Welte, 2015; Welte and Gould, 2017). Genetic studies suggest that this overlap between LD 
functions and cellular processes implicated in ALS is not mere happenstance: many genes 
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responsible for ALS, as well as for the MND Hereditary Spastic Paraplegia (HSP), play important 
roles in LD biology; on the other hand, disruption of lipid metabolism and energy homeostasis are 
prevalent in ALS (see below, Schmitt et al., 2014). 
Here we discuss the role of LDs in energy homeostasis, glia-neuron metabolic coupling, 
and protein aggregation/clearance and formulate mechanistic hypotheses on how disruption of 
these LD-mediated processes could contribute to ALS pathophysiology. Although additional 
studies are needed to assess the specific role of LDs in ALS and other MNDs, it is conceivable 
that targeting LD-related processes might lead to novel therapies for these devastating diseases.  
LDs in Metabolic Organs and MNDs 
Neurons have extremely high energy demands, and LDs are crucial for energy homeostasis in most 
cells. Might LD dysfunction promote neurodegeneration by disrupting the energy metabolism of 
neurons? At first glance, such a scenario seems unlikely because neurons derive much of their 
energy from glucose. However, when glucose is limiting, neurons use energy-rich substrates 
ultimately derived from the breakdown of FAs. Below, we discuss how LDs in various tissues 
across the organism could metabolically support MNs. We then contrast this systemic role with a 
local function in which LDs in glia provide fuel for neighbouring neurons. Finally, we consider 
whether LD functions beyond energy metabolism could directly affect MNs. 
The brain lacks fuel stores and relies on a continuous supply of glucose from peripheral 
organs, especially the liver. When glucose is scarce, the liver coverts Acetyl-CoA produced during 
FA β-oxidation into ketone bodies (KBs); KBs are transported through the bloodstream to the brain 
where they are oxidized to produce energy. FAs metabolized in the liver are, in turn, replenished 
from dietary lipids in the gut or from lipids stored in adipose tissue. In all these tissues, FAs are 
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stored as TAGs in LDs; thus LD dysfunction could indirectly impact MNs. This notion is attractive 
because many ALS genes are ubiquitously expressed, and non-cell autonomous processes can 
contribute to neuronal damage in ALS (Ilieva et al., 2009).  
A link between ALS and disrupted organismal lipid metabolism is suggested by emerging 
data on TDP-43, a ubiquitous protein encoded by the ALS10 gene. TDP-43-mediated ALS may 
be caused by either loss of its normal function, gain of new toxic functions, or possibly a 
combination of both (Polymenidou and Cleveland, 2017; Robberecht and Philips, 2013). TDP-43 
overexpressing mice display neurological symptoms, motor deficits, increased fat accumulation, 
and adipocyte hypertrophy (Stallings et al., 2013); depleting TDP-43 postnatally in mice causes 
weight loss, body fat reduction, decreased adipocyte LD content, increased FA consumption, and 
rapid death (Chiang et al., 2010). 
What is the mechanistic basis for these profound physiological changes? In skeletal 
muscles, TDP-43 depletion blocks insulin-induced trafficking of the glucose transporter Glut4 to 
the plasma membrane, by downregulating the Rab-GTPase-activating protein TBC1D1. 
Consequently, impairment in glucose uptake induces a metabolic switch towards lipids for energy 
production. Elevated FA consumption and oxidation by skeletal muscles presumably explain 
increased fat mobilization from adipose tissue (Chadt et al., 2008; Chiang et al., 2010). We 
speculate that TBC1D1 might even affect fat storage directly as the related isoform 
AS160/TBC1D4 regulates both Glut4 translocation and LD growth in adipocytes (Wu et al., 2014). 
In a yeast model for ALS, TDP-43 toxicity is enhanced by depletion of seipin (Armakola et al., 
2012). Seipin has a prominent role in LD biogenesis and growth and is the causative gene of two 
MN disorders: dHMNV and Silver syndrome (Welte et al., 2015). 
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Intriguingly, the hVAPB/ALS8 gene also controls Glut4 trafficking, both in myoblasts and 
adipocytes, and affects LD size, number and composition (Al-Anzi et al., 2015; Foster et al., 2000; 
Jansen et al., 2011). Mutations in genes controlling LD biogenesis/dynamics modify ALS8 
phenotypes in flies (Sanhueza et al., 2015), and in C. elegans and mice, VAPB depletion induces 
LD accumulation and clustering in muscles (Han et al., 2013).  In humans, mutations in spatacsin 
cause ALS and the MND HSP11, and its loss in mice induces MN degeneration, muscle atrophy 
and a decrease in the steady-state number of LDs, possibly due to defective clearance of lipids by 
lysosomes (Branchu et al., 2017). 
Evidence pointing to a metabolic switch from glucose towards lipids is also emerging in 
SOD1 mouse models of ALS: their spinal cord neurons display decreased glucose usage (Miyazaki 
et al., 2012), and a fat-rich diet restores normal body mass, delays disease onset and MN 
degeneration, and extends life expectancy (Schmitt et al., 2014). Consistent with a change in fuel 
preference in SOD1 mice, denervation of glycolytic muscle fibres, an early pre-symptomatic event, 
is preceded by increased expression of lipid-handling genes (Palamiuc et al., 2015). Increased FA 
requirements may explain why hyperlipidaemia positively correlates with survival in ALS patients 
and why they exhibit enhanced circulating levels of KBs (Schmitt et al., 2014). 
Collectively, emerging evidence links ALS to systemic disruption of lipid metabolism 
(Figure 1A), though it remains to be established whether LD defects contribute to disease 
pathology or play more direct causative roles. We propose that LD dysfunction in various 
peripheral organs could throttle energy delivery to neurons and muscles, an energy supply these 
cells depend on under disease conditions.  
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LDs in Glia-Neuron Metabolic Coupling  
Neurons also derive fuel substrates from glia. According to the astrocyte-neuron lactate shuttle 
hypothesis, under conditions of intense neuronal activity, astrocytes – a type of glia – deliver 
glucose-derived lactate to neurons for ATP production (Belanger et al., 2011). Neurons can also 
receive lactate from oligodendrocytes (glial cells in the CNS that myelinate axons), via 
monocarboxylate transporters (MCTs). MCT1 ablation leads to axon damage and neuronal 
degeneration, and MCT1 levels are reduced in affected brain regions from ALS patients and in 
SOD1 mouse models of ALS (Lee et al., 2012). Intriguingly, MCTs can also transport KBs 
(Halestrap, 2012), and emerging evidence suggests that glia provide KBs as fuel to neurons, 
suggesting a novel link between LDs and ALS.  
KBs are largely supplied by the liver; but like hepatocytes, astrocytes use FAs as primary 
metabolic fuel and produce large amount of KBs using a ketogenic machinery that is similar in 
both cell types (Guzman and Blazquez, 2001). This machinery requires the sequential action of 
three enzymes to transport FAs from the cytosol to the mitochondrial matrix. CPT1 (carnitine-
palmitoyltransferase1) on the outer mitochondrial membrane conjugates carnitine with FAs; 
CACT (carnitine-acylcarnitine translocase) transfers acylcarnitine across the inner mitochondrial 
membrane where CPT2 conjugates FAs back to Coenzyme-A for subsequent β-oxidation. Inside 
mitochondria, acetyl moieties condense to generate KBs. In vivo, loss of CPT2 leads to increased 
starvation sensitivity and reduced life span of Drosophila adults. Because these phenotypes are 
reversed by selectively restoring CPT2 expression in glia, it was proposed that KB production and 
release from glia help power the brain (Schulz et al., 2015).  
Together, these observations support a model in which disruption of KB production from 
LD-derived lipids or of their delivery may impact energy-dependent processes important for MN 
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function and survival (Figure 1B). Consistent with this idea, inactivation of CTP2 in Drosophila 
leads to selective accumulation of LDs in glia, and glia-specific CPT2 expression reverses this 
phenotype (Schulz et al., 2015).  
LDs in Neurons 
Although it used to be controversial whether neuronal LDs exist at all, they have now been clearly 
identified in axons of Aplysia (Savage et al., 1987), neuronal cultures and brain sections of 
Huntington’s disease models (Martinez-Vicente et al., 2010), cerebral cortex neurons (Renvoise 
et al., 2016), MN axons of Drosophila larvae (Papadopoulos et al., 2015), and neuroblastoma cell 
lines (Holtta-Vuori et al., 2013).  
Presence and abundance of neuronal LDs vary tremendously and may depend on variables 
such as developmental stage, nutrient or environmental conditions. In Drosophila glia, for 
example, LDs are induced by hypoxia in larvae (Bailey et al., 2015) and by neurodegeneration in 
adults (Liu et al., 2015). Sex-related differences in FA metabolism (Bakewell et al., 2006; Hoyenga 
and Hoyenga, 1982) could explain why cultured neurons isolated from females accumulate more 
LDs than neurons from males (Du et al., 2009). Neuronal LDs may also be rare or transient, making 
their identification particularly challenging. In adult mouse brain, LDs are rarely found, but they 
prominently accumulate inside neurons when their turnover is impaired by mutations in the TAG 
hydrolase DDHD2 (Inloes et al., 2014). 
DDHD2 mouse knockouts exhibit motor and cognitive dysfunctions with extensive 
neurodegeneration, and in humans, DDHD2 mutations cause a MND known as HSP54 (Inloes et 
al., 2014). DDHD2-depleted neurons exhibit swelling of axons and dendrites, and Drosophila 
neuro-muscular junctions lacking DDHD2 display fewer active zones, the sites of neurotransmitter 
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release (Schuurs-Hoeijmakers et al., 2012). We therefore speculate that excessive LDs may 
sequester and disrupt the trafficking of proteins and lipids required for synapse assembly; indeed 
LDs from mutant brains are associated with several proteins implicated in neuronal function 
(Figure 2) (Inloes et al., 2018).  
Conversely, LDs in glia are larger and more easily detected than in neurons. Heterogeneity 
in LD content across a cell population was proposed to promote metabolic specialization. In the 
liver, some cells accumulate more LDs than their neighbours and, when needed, efficiently deliver 
FAs to surrounding cells (Herms et al., 2013). This heterogeneity may represent a strategy to 
alleviate the overall risk of lipotoxicity because cells with high LD content and higher levels of 
reactive oxygen species (ROS) express specialized defence mechanisms against oxidative damage. 
Might a similar division of labour also exist within the brain, with glia as the high-lipid content 
cells? Intriguingly, astrocytes contain higher levels of anti-oxidant molecules and ROS-
detoxifying enzymes than neurons (Belanger et al., 2011). 
Indeed, there is direct evidence that LDs in glia protect neighbouring neurons from 
oxidative stress (Figure 1B). In Drosophila adults and mice, mitochondrial dysfunction promotes 
- via ROS accumulation - increased synthesis of lipids, which are then transferred from neurons to 
glia and stored in LDs (Liu et al., 2017; Liu et al., 2015). In Drosophila larvae, increased glial LD 
content due to ROS accumulation (e.g. under hypoxia conditions) is protective because if glia are 
unable to make LDs, neurons exhibit increased damage from peroxidation (Bailey et al., 2015). It 
was proposed that glial LDs sequester lipids away from the plasma membrane, especially lipids 
containing polyunsaturated FAs (PUFAs), which are particularly vulnerable to peroxidation by 
ROS. PUFAs are more protected when incorporated into TAGs within LDs than when they are in 
phospholipids of cell membranes. During ROS-induced apoptosis, PUFAs of membrane 
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phospholipids are peroxidated while their incorporation into LDs is thought to decrease their 
toxicity, suggesting that protection from oxidative stress is a general role of LDs (Li et al., 2017).  
This protective role could be relevant for ALS as oxidative stress due to mitochondrial 
dysfunction is a leading cause of MN injury in ALS (Barber and Shaw, 2010). Consistently, 
markers of lipid peroxidation are found in the cerebrospinal fluid of ALS patients and in disease 
models, suggesting that accumulation of these toxic molecules might contribute to ALS (Simpson 
et al., 2004; Smith et al., 1998). 
LDs in Protein Aggregation and Clearance  
Protein turnover is critical for ALS, as a number of ALS-linked mutations affect genes directly 
involved in protein clearance and homeostasis (Taylor et al., 2016). Emerging evidence also 
suggests that LDs play a fundamental role in protein aggregation and clearance. Below we discuss 
whether and how LD-mediated control of these processes within neurons could affect their 
function and survival. 
 When misfolded or overabundant proteins stress the ER, an elaborate machinery is 
deployed to deliver them to the ubiquitin-proteasome system for degradation (ERAD or 
endoplasmic reticulum associated protein degradation). For ApoB-100, a major component of the 
very low density lipoproteins, proteasome-mediated degradation relies on LDs. Knockdown of 
Derlin-1, an ER protein coupling the transfer of proteins from the ER lumen to the ubiquitination 
system, decreases ApoB abundance on LDs. Conversely, knockdown of UBXD8, which binds 
ubiquitinated proteins and sends them for degradation, increases ubiquitinated ApoB levels on 
LDs. UBXD8 localizes to LDs and recruits VCP/p97, a member of the (AAA+) family which 
extracts ubiquitinated proteins from large complexes and delivers them to proteasomes. Various 
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components of the ubiquitin-proteasome system also associate with LDs. These data suggest that 
Derlin dislocates ApoB to LDs where p97/VCP together with UBXD8 hands ApoB off to the 
proteasome for degradation. A similar mechanism likely operates for other proteins, e.g., because 
a wide range of ubiquitinated proteins accumulates upon UBXD8 knockdown (Figure 2) (Ohsaki 
et al., 2006; Welte and Gould, 2017). 
 Of particular relevance to ALS are the findings that the ALS8 protein hVAPB associates 
with LDs (Cermelli et al., 2006) and controls the degradation of misfolded proteins by binding to 
a similar molecular cluster which includes Derlin1, VCP/p97 and the UBXD8-like protein FAF1 
(Ernst et al., 2016). Specifically, hVAPB binds TTC39B (Huttlin et al., 2015) whose yeast 
orthologue, Ilm2, has a central role in LD-mediated clearance of misfolded proteins sequestered 
in inclusion bodies (IBs). Prior to IB clearance, IBs and LDs cluster in close proximity to each 
other, and the IB resident Ilm2 physically interacts with LD proteins. Without Ilm2, tethering 
between the two compartments fails and IBs are no longer efficiently cleared. Since IB clearing 
requires sterol ester containing LDs, LDs could be the source of a locally acting chemical 
chaperone that promotes refolding (Figure 2) (Moldavski et al., 2015). Relevant to ALS could be 
the observation that ALS8 causing proteins bind TTC39B more weakly than the wild-type 
counterpart (Huttlin et al., 2015). 
 A possible association between protein aggregates and LDs is also emerging in the nuclear 
compartment. The connection is through so-called promyelocytic leukemia (PML) nuclear bodies, 
membrane-less organelles of the nuclear matrix controlling diverse processes including 
transcriptional activity, cell senescence, and protein degradation (Janer et al., 2006; Lallemand-
Breitenbach and de The, 2010; Zhu and Brangwynne, 2015). PML bodies are present in close 
physical proximity to LDs within the nucleoplasm. This association is functionally important since 
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knockdown of the PML isoform PMLII, a key organizer of PML bodies, results in fewer nuclear 
LDs, whereas its overexpression is correlated with more LDs (Ohsaki et al., 2016). In the brains 
of ALS patients, Nuclear Inclusions (NIs) have been found that contain ubiquitin, proteasome 
components, and PML (Seilhean et al., 2004). Furthermore, the ALS10 protein TDP-43 forms NIs 
that overlap with PML bodies (Wang et al., 2002). Finally, PML proteins selectively interact with 
several misfolded proteins, including TDP-43, and mark them through SUMOylation for 
proteasome degradation (Guo et al., 2014). Although the connection between the ability of the 
PML protein to degrade misfolded proteins and to control LD biogenesis remains to be determined, 
given the precedent in the cytoplasm, it is plausible that nuclear LDs are platforms for the turnover 
of aggregated proteins.  
Mechanistic clues concerning LD-assisted protein clearance are emerging. SigR1, the 
causative gene of a juvenile form of ALS (Al-Saif et al., 2011; Prause et al., 2013), encodes a 
protein localized at ER-LD contact sites where it is proposed to compartmentalize neutral lipids 
and regulate their export from the ER to LDs (Hayashi and Su, 2003). Here, SigR1 associates with 
lipid rafts, transiently stable membrane microdomains rich in cholesterol and sphingolipids 
(Rajendran and Simons, 2005) which are also sites where neurodegenerative proteins accumulate 
and aggregate (Burke et al., 2013; Di Paolo and Kim, 2011). Might LD-associated lipid rafts 
promote the sequestration of aggregated proteins on LDs for subsequent degradation? Although 
purely speculative, future critical tests of this notion seem worthwhile, as LDs can host lipid raft 
proteins like caveolins, flotillins and stomatin (Fujimoto et al., 2001; Pol et al., 2004; Rajendran 
et al., 2007; Umlauf et al., 2004) and because the ER-associated lipid raft protein Erlin 2 is linked 
to both regulation of LD biogenesis (Wang et al., 2012) and certain MNDs (Al-Saif et al., 2012; 
Alazami et al., 2011). 
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Future Crucial Experiments  
Going forward, it will be crucial to determine to what extent disease phenotypes in ALS models 
are altered by tissue-specific modulation of LD genes. Advanced microscopy and newly developed 
LD fluorescent markers (Kassan et al., 2013; Wang et al., 2016) will make possible the mapping 
of neuronal LD dynamics. Additionally, lipidomic and proteomic approaches associated with 
genetic analyses will lay the ground for a mechanistic understanding of the LD role in MN function 
and survival. 
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Figure Legends 
 
Figure 1. How LDs in peripheral organs and in glia could affect MNs 
(A). TAGs are present in LDs in adipose tissue, muscle, and liver, and can be exchanged between 
these tissues via the bloodstream. In the liver, Fatty Acids (FAs) can be generated from TAGs and 
converted into Ketone Bodies (KBs). KBs travel through the blood to neurons where they are used 
as energy substrates. (B). Glia convert glucose into lactate that is then transferred to neurons as 
energy substrates. FAs in glial LDs are metabolized into KBs that are also transferred to neurons 
to be used as fuel. Finally, LDs in glia combat damage from Reactive Oxygen Species (ROS). 
 
Figure 2. How neuronal LDs might affect MNs 
LDs are present in neurons where they could act as organelles to sequester or release FAs, as 
platforms to refold or degrade misfolded proteins or as vehicles that traffic along axonal 
microtubules to deliver lipids or proteins. 
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